IGC Pharma Inc. (NYSE: IGC), which was formerly known as India Globalization Capital, announced Wednesday it plans to advance its drug candidate IGC-AD1 into clinical trials as a potential anti-amyloid treatment for Alzheimer’s disease. The move follows recent FDA approvals of anti-amyloid drugs from Eli Lilly and Eisai/Biogen, signaling growing …
Nearly 40 years ago, advocates made the case to the DEA’s own judge that cannabis did not meet the definition of a Schedule I controlled substance. Their case is exponentially stronger now. The post NORML Op-Ed: DEA’s Marijuana Hearing Is a Good Opportunity for Advocates To Make the Case for Rescheduling appeared first on NORML.
Cannabis and hemp business consulting firm Whitney Economics has dramatically reduced its 2030 forecast for U.S. hemp grain and fiber acreage, citing regulatory uncertainties and infrastructural challenges. The firm now projects 1 million acres by 2030, down 82% from its previous estimate. The revision could translate to approximately $3.1 billion …
394 million – How many pre-roll units were sold between January 2023 and June 2024 Cannabis pre-rolls are coming in strong. According to data from Headset, pre-roll products make up the third largest cannabis product category in the U.S. From January 2023 through June 2024, more than 394 million units …